{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T22:54:19Z","timestamp":1648508059988},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.zefq.2011.03.008","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:41:34Z","timestamp":1304210494000},"page":"157-162","source":"Crossref","is-referenced-by-count":2,"title":["Messung der Lebensqualit\u00e4t als Methode der Nutzen-Schaden-Abw\u00e4gung?"],"prefix":"10.1016","volume":"105","author":[{"given":"Thomas","family":"Kohlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.zefq.2011.03.008_bib0005","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden. Entwurf f\u00fcr Version 4.0. K\u00f6ln, 2011 [https:\/\/www.iqwig.de\/download\/IQWiG_Entwurf_Methoden_Version_4-0.pdf; 20.03.2011]"},{"key":"10.1016\/j.zefq.2011.03.008_bib0010","series-title":"Benefit-risk appraisal of medicines: A systematic approach to decision-making","author":"Mussen","year":"2009"},{"key":"10.1016\/j.zefq.2011.03.008_bib0015","unstructured":"European Medicines Agency. Benefit-risk methodology project. Work package 2 report: Application of current tools and processes for regulatory benefit-risk assessment \u2013 EMA\/549682\/2010. London, 2010."},{"key":"10.1016\/j.zefq.2011.03.008_bib0020","series-title":"Measuring health. A guide to rating scales and questionnaires","author":"McDowell","year":"2006"},{"key":"10.1016\/j.zefq.2011.03.008_bib0025","series-title":"Assessing quality of life in clinical trials","author":"Fayers","year":"2005"},{"key":"10.1016\/j.zefq.2011.03.008_bib0030","series-title":"Quality of life outcomes in clinical trials and health-care evaluation","author":"Walters","year":"2009"},{"key":"10.1016\/j.zefq.2011.03.008_bib0035","series-title":"Measuring and valuing health benefits for economic evaluation","author":"Brazier","year":"2007"},{"key":"10.1016\/j.zefq.2011.03.008_bib0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.1989.7.1.36","article-title":"Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis","volume":"7","author":"Goldhirsch","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.zefq.2011.03.008_bib0045","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/sj.bjc.6602230","article-title":"Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer","volume":"91","author":"Bernhard","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.zefq.2011.03.008_bib0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1212\/01.wnl.0000319648.65173.7a","article-title":"Quantitative risk-benefit analysis of natalizumab","volume":"71","author":"Thompson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.zefq.2011.03.008_bib0055","unstructured":"European Medicines Agency. Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorization applications of medicinal products for human use \u2013 EMEA\/CHMP\/15404\/2007. London, 2008."},{"key":"10.1016\/j.zefq.2011.03.008_bib0060","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1377\/hlthaff.26.3.684","article-title":"Assessing a structured, quantitative health outcomes apporach to drug risk-benefir analysis","volume":"26","author":"Garrison","year":"2007","journal-title":"Health Affairs"},{"key":"10.1016\/j.zefq.2011.03.008_bib0065","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/11537590-000000000-00000","article-title":"Evaluation of benefit-risk","volume":"28","author":"Garattini","year":"2010","journal-title":"Pharmacoeconomics"}],"container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921711000742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921711000742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T03:58:14Z","timestamp":1543809494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1865921711000742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1865921711000742"],"URL":"https:\/\/doi.org\/10.1016\/j.zefq.2011.03.008","relation":{},"ISSN":["1865-9217"],"issn-type":[{"value":"1865-9217","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}